+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Hepatitis C - Pipeline Review, H2 2018

  • ID: 4623003
  • Drug Pipelines
  • 399 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • Boehringer Ingelheim GmbH
  • Galactica Biotech Ltd
  • ImmunoBiology Ltd
  • Novartis AG
  • Rodos BioTarget GmbH
  • MORE
Hepatitis C - Pipeline Review, H2 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis C - Pipeline Review, H2 2018, provides an overview of the Hepatitis C (Infectious Disease) pipeline landscape.

Hepatitis C is a contagious viral infection affecting the liver. It may spread on contact with infected blood. It may be a mild condition or may extend over a longer span of time leading to various complications. The characteristic symptoms include abdominal pain, fatigue, fever, jaundice, loss of appetite, nausea and vomiting The predisposing factors of hepatitis C include dialysis, organ transplant and blood transfusion. Offspring of an infected mother also has high chances of contracting the disease. Hepatitis C can be controlled with the help of medications or a transplant at an advanced stage.

Report Highlights:

This latest pipeline guide Hepatitis C - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Hepatitis C (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hepatitis C (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis C and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 10, 13, 11, 2, 47, 33 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 1, 12 and 18 molecules, respectively.

Hepatitis C (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis C (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Hepatitis C (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hepatitis C (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hepatitis C (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hepatitis C (Infectious Disease)
Reasons to buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hepatitis C (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hepatitis C (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • Boehringer Ingelheim GmbH
  • Galactica Biotech Ltd
  • ImmunoBiology Ltd
  • Novartis AG
  • Rodos BioTarget GmbH
  • MORE
Introduction

Hepatitis C - Overview

Hepatitis C - Therapeutics Development

Hepatitis C - Therapeutics Assessment

Hepatitis C - Companies Involved in Therapeutics Development

Hepatitis C - Drug Profiles

Hepatitis C - Dormant Projects

Hepatitis C - Discontinued Products

Hepatitis C - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Hepatitis C, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Hepatitis C - Pipeline by AbbVie Inc, H2 2018

Hepatitis C - Pipeline by AIMM Therapeutics BV, H2 2018

Hepatitis C - Pipeline by Akshaya Bio Inc, H2 2018

Hepatitis C - Pipeline by Amarillo Biosciences Inc, H2 2018

Hepatitis C - Pipeline by Amarna Therapeutics BV, H2 2018

Hepatitis C - Pipeline by Beijing Kawin Technology Share-Holding Co Ltd, H2 2018

Hepatitis C - Pipeline by Beta Pharma Inc, H2 2018

Hepatitis C - Pipeline by Biotest Pharmaceuticals Corp, H2 2018

Hepatitis C - Pipeline by Biotron Ltd, H2 2018

Hepatitis C - Pipeline by Boehringer Ingelheim GmbH, H2 2018

Hepatitis C - Pipeline by Bolder Biotechnology Inc, H2 2018

Hepatitis C - Pipeline by Bristol-Myers Squibb Co, H2 2018

Hepatitis C - Pipeline by Cocrystal Pharma Inc, H2 2018

Hepatitis C - Pipeline by ContraVir Pharmaceuticals Inc, H2 2018

Hepatitis C - Pipeline by DEKK-TEC Inc, H2 2018

Hepatitis C - Pipeline by Ennaid Therapeutics LLC, H2 2018

Hepatitis C - Pipeline by F. Hoffmann-La Roche Ltd, H2 2018

Hepatitis C - Pipeline by Galactica Biotech Ltd, H2 2018

Hepatitis C - Pipeline by Genecode AS, H2 2018

Hepatitis C - Pipeline by GeneCure LLC, H2 2018

Hepatitis C - Pipeline by Genoscience Pharma, H2 2018

Hepatitis C - Pipeline by Gilead Sciences Inc, H2 2018

Hepatitis C - Pipeline by GinkgoPharma Co Ltd, H2 2018

Hepatitis C - Pipeline by GlaxoSmithKline Plc, H2 2018

Hepatitis C - Pipeline by ImmunoBiology Ltd, H2 2018

Hepatitis C - Pipeline by Immunotope Inc, H2 2018

Hepatitis C - Pipeline by Inovio Pharmaceuticals Inc, H2 2018

Hepatitis C - Pipeline by Integrated BioTherapeutics Inc, H2 2018

Hepatitis C - Pipeline by Kineta Inc, H2 2018

Hepatitis C - Pipeline by Medivir AB, H2 2018

Hepatitis C - Pipeline by Merck & Co Inc, H2 2018

Hepatitis C - Pipeline by Microbio Co Ltd, H2 2018

Hepatitis C - Pipeline by MultiCell Technologies Inc, H2 2018

Hepatitis C - Pipeline by Novalex Therapeutics Inc, H2 2018

Hepatitis C - Pipeline by Novartis AG, H2 2018

Hepatitis C - Pipeline by NovaTarg Therapeutics Inc, H2 2018

Hepatitis C - Pipeline by Ono Pharmaceutical Co Ltd, H2 2018

Hepatitis C - Pipeline by Pfizer Inc, H2 2018

Hepatitis C - Pipeline by PharmaEssentia Corp, H2 2018

Hepatitis C - Pipeline by Presidio Pharmaceuticals Inc, H2 2018

List of Figures

Number of Products under Development for Hepatitis C, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AbbVie Inc
  • AIMM Therapeutics BV
  • Akshaya Bio Inc
  • Amarillo Biosciences Inc
  • Amarna Therapeutics BV
  • Beijing Kawin Technology Share-Holding Co Ltd
  • Beta Pharma Inc
  • Biotest Pharmaceuticals Corp
  • Biotron Ltd
  • Boehringer Ingelheim GmbH
  • Bolder Biotechnology Inc
  • Bristol-Myers Squibb Co
  • Cocrystal Pharma Inc
  • ContraVir Pharmaceuticals Inc
  • DEKK-TEC Inc
  • Ennaid Therapeutics LLC
  • F. Hoffmann-La Roche Ltd
  • Galactica Biotech Ltd
  • Genecode AS
  • GeneCure LLC
  • Genoscience Pharma
  • Gilead Sciences Inc
  • GinkgoPharma Co Ltd
  • GlaxoSmithKline Plc
  • ImmunoBiology Ltd
  • Immunotope Inc
  • Inovio Pharmaceuticals Inc
  • Integrated BioTherapeutics Inc
  • Kineta Inc
  • Medivir AB
  • Merck & Co Inc
  • Microbio Co Ltd
  • MultiCell Technologies Inc
  • Novalex Therapeutics Inc
  • Novartis AG
  • NovaTarg Therapeutics Inc
  • Ono Pharmaceutical Co Ltd
  • Pfizer Inc
  • PharmaEssentia Corp
  • Presidio Pharmaceuticals Inc
  • Profectus BioSciences Inc
  • Regulus Therapeutics Inc
  • Rodos BioTarget GmbH
  • Sino Biopharmaceutical Ltd
  • Sudershan Biotech Ltd
  • TaiGen Biotechnology Co Ltd
  • Therapure Biopharma Inc
  • THEVAX Genetics Vaccine USA Inc
  • Toray Industries Inc
  • Vakzine Projekt Management GmbH
  • Vaxart Inc
  • Vectorite Biomedical Inc
  • Vertex Pharmaceuticals Inc
  • WhanIn Pharmaceutical Co Ltd
  • Zylacta Corp
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4623003
Adroll
adroll